Literature DB >> 26869289

Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.

Katelyn N Nelson1, April N Meyer1, Asma Siari2, Alexandre R Campos3, Khatereh Motamedchaboki3, Daniel J Donoghue4.   

Abstract

UNLABELLED: Fibroblast growth factor receptors (FGFR) are critical for cell proliferation and differentiation. Mutation and/or translocation of FGFRs lead to aberrant signaling that often results in developmental syndromes or cancer growth. As sequencing of human tumors becomes more frequent, so does the detection of FGFR translocations and fusion proteins. The research conducted in this article examines a frequently identified fusion protein between FGFR3 and transforming acidic coiled-coil containing protein 3 (TACC3), frequently identified in glioblastoma, lung cancer, bladder cancer, oral cancer, head and neck squamous cell carcinoma, gallbladder cancer, and cervical cancer. Using titanium dioxide-based phosphopeptide enrichment (TiO2)-liquid chromatography (LC)-high mass accuracy tandem mass spectrometry (MS/MS), it was demonstrated that the fused coiled-coil TACC3 domain results in constitutive phosphorylation of key activating FGFR3 tyrosine residues. The presence of the TACC coiled-coil domain leads to increased and altered levels of FGFR3 activation, fusion protein phosphorylation, MAPK pathway activation, nuclear localization, cellular transformation, and IL3-independent proliferation. Introduction of K508R FGFR3 kinase-dead mutation abrogates these effects, except for nuclear localization which is due solely to the TACC3 domain. IMPLICATIONS: These results demonstrate that FGFR3 kinase activity is essential for the oncogenic effects of the FGFR3-TACC3 fusion protein and could serve as a therapeutic target, but that phosphorylated tyrosine residues within the TACC3-derived portion are not critical for activity. Mol Cancer Res; 14(5); 458-69. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26869289     DOI: 10.1158/1541-7786.MCR-15-0497

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  34 in total

1.  Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.

Authors:  April N Meyer; Peggy Modaff; Clark G Wang; Elizabeth Wohler; Nara L Sobreira; Daniel J Donoghue; Richard M Pauli
Journal:  Am J Med Genet A       Date:  2020-12-02       Impact factor: 2.802

Review 2.  FGFR-TACC gene fusions in human glioma.

Authors:  Anna Lasorella; Marc Sanson; Antonio Iavarone
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 3.  Targeting FGFR in Squamous Cell Carcinoma of the Lung.

Authors:  Neda Hashemi-Sadraei; Nasser Hanna
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

4.  HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.

Authors:  Tao Li; Farideh Mehraein-Ghomi; M Elizabeth Forbes; Sanjeev V Namjoshi; E Ashley Ballard; Qianqian Song; Ping-Chieh Chou; Xuya Wang; Brittany C Parker Kerrigan; Frederick F Lang; Glenn Lesser; Waldemar Debinski; Xuejun Yang; Wei Zhang
Journal:  Mol Ther       Date:  2022-02-10       Impact factor: 11.454

5.  Kinase Activity of Fibroblast Growth Factor Receptor 3 Regulates Activity of the Papillomavirus E2 Protein.

Authors:  Fang Xie; Marsha DeSmet; Sriramana Kanginakudru; Leny Jose; Sara P Culleton; Timra Gilson; Chengxin Li; Elliot J Androphy
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

6.  Investigating the impact of the phosphorylation status of tyrosine residues within the TACC domain of TACC3 on microtubule behavior during axon growth and guidance.

Authors:  Burcu Erdogan; Riley M St Clair; Garrett M Cammarata; Timothy Zaccaro; Bryan A Ballif; Laura Anne Lowery
Journal:  Cytoskeleton (Hoboken)       Date:  2020-07-06

7.  Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked.

Authors:  Amin H Nassar; Kevin Lundgren; Mark Pomerantz; Eliezer Van Allen; Lauren Harshman; Atish D Choudhury; Mark A Preston; Graeme S Steele; Kent W Mouw; Xiao X Wei; Bradley A McGregor; Toni K Choueiri; Joaquim Bellmunt; David J Kwiatkowski; Guru P Sonpavde
Journal:  JCO Precis Oncol       Date:  2018-05-16

8.  Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.

Authors:  Benedetta Lombardi; Paul Ashford; Aurelio A Moya-Garcia; Aleksander Rust; Mark Crawford; Sarah V Williams; Margaret A Knowles; Matilda Katan; Christine Orengo; Jasminka Godovac-Zimmermann
Journal:  Oncotarget       Date:  2017-10-25

Review 9.  Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.

Authors:  Xue Cai; Michael E Sughrue
Journal:  Oncotarget       Date:  2017-12-20

10.  Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.

Authors:  Ryo Tamura; Kosuke Yoshihara; Tetsuya Saito; Ryosuke Ishimura; Juan Emmanuel Martínez-Ledesma; Hu Xin; Tatsuya Ishiguro; Yutaro Mori; Kaoru Yamawaki; Kazuaki Suda; Seiya Sato; Hiroaki Itamochi; Teiichi Motoyama; Yoichi Aoki; Shujiro Okuda; Cristine R Casingal; Hirofumi Nakaoka; Ituro Inoue; Roel G W Verhaak; Masaaki Komatsu; Takayuki Enomoto
Journal:  Oncogenesis       Date:  2018-01-23       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.